Blood Cancer Trials
The following listings are our current trials. If you have questions or want to learn more about the trial, please contact us and provide the trial ID number listed with the description.
Alliance A041701
Status: Recruiting | Phase II/III
Official Title: A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Study Purpose: To compare the usual treatment alone to using uproleselan plus the usual treatment. Learn more.
Alliance A041702
Status: Recruiting | Phase III
Official Title: A Randomized Phase III study of Ibrutinib Plus Obinutuzumab versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 years of age) with Chronic Lymphocytic Leukemia (CLL)
Study Purpose: To compare the usual treatment alone (Ibrutinib plus Obinutuzumab) to using Venetoclax plus the usual treatment. The addition of Venetoclax to the usual treatment could prevent your chronic lymphocytic leukemia from returning. Learn more.
Alliance A051701
Status: Recruiting | Phase II
Official Title: Testing the Addition of A New Anti-Cancer Drug Venetoclax, To Usual Chemotherapy For High Grade Cell Lymphomas
Study Purpose: To determine if adding a new drug, venetoclax, to the usual combination of drugs can lower the chance of lymphoma returning or getting worse. Also, to find out if this approach is better or worse than the usual approach for lymphoma. Learn more.
CIBMTR Research Database
Status: Recruiting | Phase: Not Applicable
Official Title: Center for International Blood and Marrow Transplant Research: Protocol for a Research Database for Hematopoietic Cell Transplantation and Cellular Therapies
Study Purpose: To gather health information from patients receiving stem cell transplants that can be used to find ways to make stem cell transplants work better. Learn more.
SWOG S1712
Status: Recruiting | Phase II
Official Title: A randomized phase II study of ruxolitinib (NCS-752295) in combination with BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia (CML) patients with molecular evidence of disease
Study Purpose: The purpose of this study is to compare the good and bad effects of adding the study drug ruxolitinib to the usual chemotherapy (called TKI, which is either dasatinib or nilotinib) with the good and bad effects of using TKI alone. Learn more.
SWOG S1803
Status: Recruiting | Phase III
Official Title: Phase III study of daratumumab/rHuPH20 (NSC-810307) + lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapy in patients with multiple myeloma (MM) using minimal residual disease to direct therapy duration (dramatic study)
Study Purpose: The purpose of this part of the study (screening consent) is to allow your study doctor to follow your progress through your transplant to see if you can take part in the treatment portion of the study. Learn more.